Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022
February 24, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., and CHICAGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal...
GIMOTI® Commercialization Update
February 17, 2022 08:30 ET
|
Evoke Pharma, Inc.
New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com Expanded Coverage with recent...
Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
February 02, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif. and CHICAGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI)...
Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
January 04, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (G.I.) diseases,...
Evoke Pharma Reports Third Quarter 2021 Financial Results
November 10, 2021 16:05 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021
November 03, 2021 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases,...
Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research Study
October 20, 2021 08:30 ET
|
Evoke Pharma, Inc.
Health care practitioners’ perception of nasal route of administration similar to IV; 92% intend to prescribe GIMOTI Evoke attending American College of Gastroenterology (ACG) Annual Conference in...
Evoke Pharma’s Commercial Partner EVERSANA, Receives PM360’s Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTI
September 29, 2021 08:30 ET
|
Evoke Pharma, Inc.
Award for “Spray Away” Campaign seeking to drive patient and provider awareness for the novel nasal spray treatment of symptoms of Diabetic Gastroparesis SOLANA BEACH, Calif., Sept. 29, 2021 (GLOBE...
Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 01, 2021 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
Evoke Pharma Reports Second Quarter 2021 Financial Results
August 12, 2021 16:05 ET
|
Evoke Pharma, Inc.
Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti® Extends cash runway into third quarter of 2022 SOLANA BEACH, Calif., Aug....